^
Association details:
| Biomarker: | miR-192-5p overexpression |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
Published date:
02/20/2023
Excerpt:
...44 patients diagnosed with high-risk MDS were treated with a combination of azacitidine and lenalidomide...Kaplan-Meier analyses showed a significant correlation between high levels of miR-192-5p after 4 cycles of therapy and overall survival or leukemia-free survival, that was stronger in responders...This study shows that high levels of miR-192-5p are associated with higher overall survival and leukemia-free survival in myelodysplastic syndromes responding to azacitidine and lenalidomide.
Secondary therapy:
azacitidine
DOI:
10.1186/s13148-023-01441-9
